Scientists for the first time have used CRISPR gene editing to halt the progression of Duchenne muscular dystrophy (DMD) in a large mammal, according to a study by UT Southwestern that provides a strong indication that a lifesaving treatment may be in the pipeline.
The research published in Science documents unprecedented improvement in the muscle fibers of dogs with DMD – the most common fatal genetic disease in children, caused by a mutation that inhibits the production of dystrophin, a protein critical for muscle function.
Researchers used a single-cut gene-editing technique to restore dystrophin in muscle and heart tissue by up to 92 percent of normal levels. Scientists have estimated a 15 percent threshold is needed to significantly help patients.
“Children with DMD often die either because their heart loses the strength to pump, or their diaphragm becomes too weak to breathe,” said Dr. Eric Olson, Director of UT Southwestern’s Hamon Center for Regenerative Science and Medicine. “This encouraging level of dystrophin expression would hopefully prevent that from happening.”
DMD, which affects one in 5,000 boys, leads to muscle and heart failure, and premature death by the early 30s. Patients are forced into wheelchairs as their muscles degenerate and eventually onto respirators as their diaphragms weaken. No effective treatment exists, though scientists have known for decades that a defect in the dystrophingene causes the condition.
The Science study establishes the proof-of-concept for single-cut gene editing in dystrophic muscle and represents a major step toward a clinical trial. Already Dr. Olson’s team has corrected DMD mutations in mice and human cells by making single cuts at strategic points of the mutated DNA.
The latest research applied the same technique in four dogs that shared the type of mutation most commonly seen in DMD patients. Scientists used a harmless virus called adeno-associated virus (AAV) to deliver CRISPR gene-editing components to exon 51, one of the 79 exons that comprise the dystrophin gene.
CRISPR edited the exon, and within several weeks the missing protein was restored in muscle tissue throughout the body, including 92 percent correction in the heart and 58 percent in the diaphragm, the main muscle needed for breathing.
“Our strategy is different from other therapeutic approaches for DMD because it edits the mutation that causes the disease and restores normal expression of the repaired dystrophin,” said Dr. Leonela Amoasii, lead author of the study and Assistant Instructor of Molecular Biology in Dr. Olson’s lab. “But we have more to do before we can use this clinically.”
The lab will next conduct longer-term studies to measure whether the dystrophin levels remain stable and to ensure the gene edits do not have adverse side effects.
Dr. Olson hopes the next step beyond dogs is a clinical trial, which would be among several that UT Southwestern’s gene therapy center aims to launch in the coming years to address numerous deadly childhood diseases.
In the meantime, Dr. Olson’s recent work has spawned a biotechnology company, Exonics Therapeutics Inc., which is working to further optimize and bring this technology to the clinic. Exonics intends to extend the approach to additional DMD mutations, as well as other neuromuscular diseases. Exonics has licensed the technology from UT Southwestern.
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Capricor Therapeutics Appoints Xavier Avat as Chief Business Officeron May 25, 2022 at 6:00 am
Capricor Expands Senior Management Team to Build Commercial Strategy for Lead Asset, CAP-1002, and Further Develop Partnering Strategy for Proprietary Exosome Platform Formerly at Edwards Lifesciences ...
- A Kansas man with a rare disorder spent decades advocating for gene therapy. It may never help himon May 24, 2022 at 6:00 am
Donavon Decker became, in more ways than one, an ambassador of limb girdle muscular dystrophy type 2D, a degenerative disorder. But decades after he participated in patient trials and fundraised for ...
- My Top Tips for Traveling With Duchenne MDon May 23, 2022 at 7:04 am
The last time I traveled on my own without my parents was last May, when my friends and I went to Hawaii. While my parents did come with us, they kept to the hotel room and let us explore. Being away ...
- Daily Steroids Slow Duchenne Muscular Dystrophy Progressionon May 22, 2022 at 10:38 am
Daily steroid doses for children with Duchenne muscular dystrophy (DMD) mark a significant change in treating the disease.
- Scientists home in on cause of Duchenne gene therapy side effecton May 17, 2022 at 10:34 am
An unusual collaboration among gene therapy developers suggests certain mutations could be behind "peculiar" side effects experienced by several patients treated in clinical trials.
- Obesity and loss of ambulation are associated with lower extremity oedema in Duchenne muscular dystrophyon May 12, 2022 at 5:00 pm
Patients with Duchenne muscular dystrophy have multiple risk factors for lower extremity oedema. This study sought to define the frequency and predictors of oedema. Patients aged ...
- Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophyon May 12, 2022 at 5:07 am
Pre-IND meeting request granted by FDA's Division of Neurology IBOSTON, May 12, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), ...
- Parent Project Muscular Dystrophy Announces Pediatric Certified Duchenne Care Center, Helen DeVos Children's Hospitalon May 11, 2022 at 7:42 am
Leading Duchenne Organization Expands Certification of Clinics that Provide Optimal Care for People with Duchenne Muscular Dystrophy with 1st Clinic in Michigan HDVCH is a growing center and ...
- Parent Project Muscular Dystrophy Announces Pediatric Certified Duchenne Care Center, Helen DeVos Children's Hospitalon May 11, 2022 at 7:03 am
Leading Duchenne Organization Expands Certification of Clinics that Provide Optimal Care for People with Duchenne Muscular Dystrophy with 1st Clinic in Michigan WASHINGTON, May 11, 2022 ...
- Global Duchenne Muscular Dystrophy Therapeutics Market Size 2022, Production, Consumption, Export and Import by Region, Forecast Report 2029on May 10, 2022 at 11:01 pm
Duchenne Muscular Dystrophy Therapeutics Market provides a full-scale analysis of major players in Duchenne Muscular Dystrophy Therapeutics Based Customer Support Messaging Platform industry.
via Bing News